Intravitreal corticosteroid MWS 2012 Han.ppt (Read-Only)

More documents

Recommendations

Info

12/12/11 Iluvien for DME: long term results Ø Subgroup analysis of duration of DME at baseline (0.2µg/d, 3 year results): If
12/12/11 Mean Change in Visual Acuity* at Follow-up Visits: Pseudophakic Eyes at Baseline Cumulative Probability of Cataract Surgery Over 2-Years Change in Visual Acuity from Baseline (letter score) 11 10 9 8 7 6 5 4 3 2 1 0 0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76 80 84 88 92 96 100104 Visit Week *Truncated ± 30 letters Sham+Prompt Laser Ranibizumab+Prompt Laser Ranibizumab+Deferred Laser Triamcinolone+Prompt Laser N = 205 (52 weeks) N = 199 (68 weeks) N = 196 (84 weeks) N = 206 (104 weeks) 25 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 0 120 4 240 8 360 12 480 16 600 20 720 24 Month 74% 18% 16% Sham (N = 192) Ranibizumab (N = 265) Triamcinolone (N = 124) 26 Iniaon of IOP-‐lowering medicaons* or glaucoma surgery (2 year follow-‐up) IOP meds Glauc surgery Ø TA + prompt laser (n=93): 50% (2 eyes, 1.1%) Ø Ranibizumab (n=34): 9% (1 eye, 0.2%) Ø Sham + prompt laser (n=32): 11% (1 eye, 0.3%) Ø P
Page 1 and 2: 12/12/11 Disclosure Intravitreal Co
Page 3 and 4: 12/12/11 Intravitreal triamcinolone
Page 5: 12/12/11 Ozurdex for DME (PLACID tr
Page 9 and 10: 12/12/11 CRUISE Trial Mean Change f

Intravitreal corticosteroid MWS 2012 Han.ppt (Read-Only)

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?